- Home
- WKSP vs MEIP Comparison
WKSP vs MEIP Comparison
Compare WKSP & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- MEIP
- Stock Information
- Founded
- WKSP 2003
- MEIP 2000
- Country
- WKSP United States
- MEIP United States
- Employees
- WKSP N/A
- MEIP N/A
- Industry
- WKSP Auto Parts:O.E.M.
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- MEIP Health Care
- Exchange
- WKSP Nasdaq
- MEIP Nasdaq
- Market Cap
- WKSP 21.3M
- MEIP 18.0M
- IPO Year
- WKSP N/A
- MEIP 2003
- Fundamental
- Price
- WKSP $0.95
- MEIP $2.52
- Analyst Decision
- WKSP
- MEIP Hold
- Analyst Count
- WKSP 0
- MEIP 2
- Target Price
- WKSP N/A
- MEIP $7.00
- AVG Volume (30 Days)
- WKSP 2.8M
- MEIP 19.5K
- Earning Date
- WKSP 11-13-2024
- MEIP 02-11-2025
- Dividend Yield
- WKSP N/A
- MEIP N/A
- EPS Growth
- WKSP N/A
- MEIP N/A
- EPS
- WKSP N/A
- MEIP N/A
- Revenue
- WKSP $6,395,908.00
- MEIP N/A
- Revenue This Year
- WKSP $366.78
- MEIP N/A
- Revenue Next Year
- WKSP $311.43
- MEIP $300.00
- P/E Ratio
- WKSP N/A
- MEIP N/A
- Revenue Growth
- WKSP 776.97
- MEIP 33.76
- 52 Week Low
- WKSP $0.36
- MEIP $2.48
- 52 Week High
- WKSP $1.66
- MEIP $6.52
- Technical
- Relative Strength Index (RSI)
- WKSP 62.36
- MEIP 29.24
- Support Level
- WKSP $0.78
- MEIP $2.65
- Resistance Level
- WKSP $1.09
- MEIP $2.89
- Average True Range (ATR)
- WKSP 0.11
- MEIP 0.12
- MACD
- WKSP 0.03
- MEIP -0.02
- Stochastic Oscillator
- WKSP 69.11
- MEIP 8.89
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.